Core Viewpoint - Tevogen Bio emphasizes the importance of addressing the challenges posed by short-selling on healthcare innovation and its commitment to advancing affordable medical solutions while maintaining transparency and fairness in the market [2][3][4]. Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing precision T cell therapies using CD8+ cytotoxic T lymphocytes to treat infectious diseases and cancers, aiming to meet significant unmet medical needs [5]. - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and additional pending patents related to artificial intelligence [5]. Strategic Initiatives - Tevogen Bio has formed a collaboration with Microsoft to explore AI applications in biotechnology, which is part of its broader strategy to enhance its product pipeline and ensure patient accessibility [2][5]. - The leadership believes that sustainable healthcare innovation relies on advanced science and innovative business models to ensure patient access [5][6]. Market Position and Challenges - The company faces pressure on its share price despite its advancements, raising concerns about the impact of short-selling on its focus and priorities [2][3]. - Tevogen Bio's leadership advocates for fair market participation, emphasizing the need for transparency and fairness for retail investors [4].
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity